Literature DB >> 21812004

Distribution characteristics of clarithromycin and azithromycin, macrolide antimicrobial agents used for treatment of respiratory infections, in lung epithelial lining fluid and alveolar macrophages.

Kohei Togami1, Sumio Chono, Kazuhiro Morimoto.   

Abstract

The distribution characteristics of clarithromycin (CAM) and azithromycin (AZM), macrolide antimicrobial agents, in lung epithelial lining fluid (ELF) and alveolar macrophages (AMs) were evaluated. In the in vivo animal experiments, the time-courses of the concentrations of CAM and AZM in ELF and AMs following oral administration (50 mg/kg) to rats were markedly higher than those in plasma, and the area under the drug concentration-time curve (AUC) ratios of ELF/plasma of CAM and AZM were 12 and 2.2, and the AUC ratios of AMs/ELF were 37 and 291, respectively. In the in vitro transport experiments, the basolateral-to-apical transport of CAM and AZM through model lung epithelial cell (Calu-3) monolayers were greater than the apical-to-basolateral transport. MDR1 substrates reduced the basolateral-to-apical transport of CAM and AZM. In the in vitro uptake experiments, the intracellular concentrations of CAM and AZM in cultured AMs (NR8383) were greater than the extracellular concentrations. The uptake of CAM and AZM by NR8383 was inhibited by ATP depletors. These data suggest that the high distribution of CAM and AZM to AMs is due to the sustained distribution to ELF via MDR1 as well as the high uptake by the AMs themselves via active transport mechanisms.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21812004     DOI: 10.1002/bdd.767

Source DB:  PubMed          Journal:  Biopharm Drug Dispos        ISSN: 0142-2782            Impact factor:   1.627


  15 in total

1.  Comparison of plasma, epithelial lining fluid, and alveolar macrophage concentrations of solithromycin (CEM-101) in healthy adult subjects.

Authors:  Keith A Rodvold; Mark H Gotfried; J Gordon Still; Kay Clark; Prabhavathi Fernandes
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

2.  Transport of Azithromycin into Extravascular Space in Rats.

Authors:  Shinji Kobuchi; Miki Aoki; Chiaki Inoue; Hiroyuki Murakami; Akiko Kuwahara; Tsutomu Nakamura; Hiroyuki Yasui; Yukako Ito; Kanji Takada; Toshiyuki Sakaeda
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

3.  Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.

Authors:  Aline Vidal Lacerda Gontijo; Julien Brillault; Nicolas Grégoire; Isabelle Lamarche; Patrice Gobin; William Couet; Sandrine Marchand
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

4.  Pharmacokinetics, microbial response, and pulmonary outcomes of multidose intravenous azithromycin in preterm infants at risk for Ureaplasma respiratory colonization.

Authors:  L Marcela Merchan; Hazem E Hassan; Michael L Terrin; Ken B Waites; David A Kaufman; Namasivayam Ambalavanan; Pamela Donohue; Susan J Dulkerian; Robert Schelonka; Laurence S Magder; Sagar Shukla; Natalie D Eddington; Rose M Viscardi
Journal:  Antimicrob Agents Chemother       Date:  2014-11-10       Impact factor: 5.191

5.  Clarithromycin Suppresses Chloride Channel Accessory 1 and Inhibits Interleukin-13-Induced Goblet Cell Hyperplasia in Human Bronchial Epithelial Cells.

Authors:  Akimichi Nagashima; Masaharu Shinkai; Masahiro Shinoda; Tadasuke Shimokawaji; Yasuhiro Kimura; Kei Mishina; Takashi Sato; Mariko Toda; Yoshiaki Inayama; Bruce K Rubin; Takeshi Kaneko
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

6.  Intrapulmonary distribution and pharmacokinetics of laninamivir, a neuraminidase inhibitor, after a single inhaled administration of its prodrug, laninamivir octanoate, in healthy volunteers.

Authors:  Hitoshi Ishizuka; Kaoru Toyama; Satoshi Yoshiba; Hiromi Okabe; Hidetoshi Furuie
Journal:  Antimicrob Agents Chemother       Date:  2012-04-23       Impact factor: 5.191

7.  Effect of clarithromycin in inflammatory markers of patients with ventilator-associated pneumonia and sepsis caused by Gram-negative bacteria: results from a randomized clinical study.

Authors:  Aikaterini Spyridaki; Maria Raftogiannis; Anastasia Antonopoulou; Thomas Tsaganos; Christina Routsi; Fotini Baziaka; Vassiliki Karagianni; Maria Mouktaroudi; Pantelis Koutoukas; Aimilia Pelekanou; Anastasia Kotanidou; Stylianos E Orfanos; Jos W M van der Meer; Mihai G Netea; Evangelos J Giamarellos-Bourboulis
Journal:  Antimicrob Agents Chemother       Date:  2012-05-07       Impact factor: 5.191

Review 8.  Clinical experimentation with aerosol antibiotics: current and future methods of administration.

Authors:  Paul Zarogoulidis; Ioannis Kioumis; Konstantinos Porpodis; Dionysios Spyratos; Kosmas Tsakiridis; Haidong Huang; Qiang Li; J Francis Turner; Robert Browning; Wolfgang Hohenforst-Schmidt; Konstantinos Zarogoulidis
Journal:  Drug Des Devel Ther       Date:  2013-10-02       Impact factor: 4.162

Review 9.  The role of macrolides in childhood non-cystic fibrosis-related bronchiectasis.

Authors:  R Masekela; R J Green
Journal:  Mediators Inflamm       Date:  2012-04-18       Impact factor: 4.711

10.  Retrospective investigation of combination therapy with clarithromycin and levofloxacin for pulmonary Mycobacterium avium complex disease.

Authors:  Hitoshi Shimomura; Airi Ono; Keiko Imanaka; Toru Majima; Hidenori Masuyama; Tsugumichi Sato; Takao Aoyama
Journal:  J Pharm Health Care Sci       Date:  2015-09-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.